Novartis said recently that a review of the outcomes of a test of diabetics who had heart failure in which their left ventricle could no longer contract as it should indicates Entresto pills helped those diabetics better manage their blood sugar levels than enalapril.
In the test, Entresto brought down the amounts of blood sugar levels for the previous 60 to 90 days, following a year that the diabetics were taking it for heart failure. The outcomes revealed that the diabetics retained the blood sugar level during three years when scientists continued to watch them, a Novartis release said.
The scientists running the test ran Entresto against enalapril and looked at how each impacted blood sugar levels at the time of the test and then again after one year, two years and three years. With the outcomes of the test, Entresto brought down levels .26 percent in the first year of additional observation, while enalapril brought down the levels .16 percent over that time.
After three years of additional observation, the scientists found that blood sugar levels in those who took Entresto stayed lower than those who took enalapril, the release said.